Abstract: The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patients internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding an improved leucine catabolism enzyme with higher activity and/or specificity for leucine over other branched chain amino acids, such as isoleucine or valine.

Abstract: An embodiment in accordance with the present invention provides a non-invasive solution to risk stratify the risk of in arrhythmia in patients with TOF. Currently, no reliable method for non-invasive risk stratification exists. In the realm of congenital heart disease, cardiac MRI is now used routinely for patients with Tetralogy of Fallot (TOF), the most common form of cyanotic congenital heart disease. An innovative platform for using clinical MRI data to create 3D electromechanical models of the heart enables predictions of whether or not patients with ischemic heart disease have the substrate for arrhythmia and what their relative risk for such an event is. An embodiment of the current invention provides a non-invasive solution to risk stratify the risk of arrhythmia in patients with TOF. Currently, no reliable method for non-invasive risk stratification exists.

Abstract: An embodiment in accordance with the present invention provides a non-invasive solution to risk stratify the risk of in arrhythmia in patients with TOF. Currently, no reliable method for non-invasive risk stratification exists. In the realm of congenital heart disease, cardiac MRI is now used routinely for patients with Tetralogy of Fallot (TOF), the most common form of cyanotic congenital heart disease. An innovative platform for using clinical MRI data to create 3D electromechanical models of the heart enables predictions of whether or not patients with ischemic heart disease have the substrate for arrhythmia and what their relative risk for such an event is. An embodiment of the current invention provides a non-invasive solution to risk stratify the risk of arrhythmia in patients with TOF. Currently, no reliable method for non-invasive risk stratification exists.

Abstract: According to some embodiments of the invention, a method for providing an atrial fibrillation (AF) ablation treatment plan includes receiving imaging data for at least a portion of an atrial region of a subject's heart, and processing the imaging data to characterize tissue as one of fibrotic tissue or non-fibrotic tissue. The method further includes calculating a metric of spatial distribution of at least a portion of the tissue characterized as fibrotic tissue from the processing the imaging data, identifying a cardiac tissue ablation target based on the metric, and providing an AF treatment plan that includes the cardiac tissue ablation target as at least a portion of the AF treatment plan.

Abstract: According to some embodiments of the invention, a method for providing an atrial fibrillation (AF) ablation treatment plan includes receiving imaging data for at least a portion of an atrial region of a subject's heart, and processing the imaging data to characterize tissue as one of fibrotic tissue or non-fibrotic tissue. The method further includes calculating a metric of spatial distribution of at least a portion of the tissue characterized as fibrotic tissue from the processing the imaging data, identifying a cardiac tissue ablation target based on the metric, and providing an AF treatment plan that includes the cardiac tissue ablation target as at least a portion of the AF treatment plan.